Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Pardeep Nijhawan is Chief Executive Officer at Edesa Biotech. OQRO lists 24 transactions filed with the SEC under this name, the latest on Nov 5, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
24
Companies involved
1
6 buys, median +19.2 pts vs S&P 500, beat it 3 of 6 times.
Average +16.4 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Mar 3, 2026 to Mar 11, 2026, measured from the first close after the filing. Past results, not a forecast.
6 purchases disclosed; 33% of the 6 measured at 90 days finished ahead of the index. $1,000 placed after each of the 6 purchases disclosed since 2025-11-16 would be worth $2.1K today ($6K put in); the same in the S&P 500 (SPY): $6.7K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Edesa BiotechEDSA
24 disclosures · Dec 2025 – Nov 2026 · 8 bought
Nov 4, 202619Kdisclosed Nov 5
DetailsOfficial recordOct 28, 202628Kdisclosed Oct 29
DetailsOfficial recordOct 5, 20266,893disclosed Oct 7
DetailsOfficial recordSep 1, 20265,714disclosed Sep 2
DetailsOfficial recordAug 3, 20265,324disclosed Aug 5
DetailsOfficial recordJul 2, 20263,378disclosed Jul 3
DetailsOfficial recordJun 16, 2026154Kdisclosed Jun 17
DetailsOfficial recordJun 1, 20261,671disclosed Jun 2
DetailsOfficial recordMay 27, 202697Kdisclosed May 30
DetailsOfficial recordMay 1, 20261,159disclosed May 2
DetailsOfficial recordApr 1, 20262,578disclosed Apr 11
DetailsOfficial recordMar 10, 2026Bought~$6.6Kdisclosed Mar 11
DetailsOfficial recordMar 5, 2026Bought~$39Kdisclosed Mar 7
DetailsOfficial recordMar 4, 2026Bought~$43Kdisclosed Mar 6
DetailsOfficial recordMar 3, 2026Bought~$36Kdisclosed Mar 5
DetailsOfficial recordMar 2, 2026Bought~$4Kdisclosed Mar 4
DetailsOfficial recordMar 2, 2026Bought~$2.3Kdisclosed Mar 4
DetailsOfficial recordFeb 27, 2026Bought~$67Kdisclosed Mar 3
DetailsOfficial recordFeb 26, 2026Bought~$32Kdisclosed Mar 3
DetailsOfficial recordFeb 19, 202682Kdisclosed Mar 3
DetailsOfficial recordMar 2, 202610Kdisclosed Mar 3
DetailsOfficial recordFeb 2, 202611Kdisclosed Feb 3
DetailsOfficial recordJan 5, 202610Kdisclosed Jan 6
DetailsOfficial recordDec 1, 20258,766disclosed Dec 3
DetailsOfficial recordAs of the latest filing on , Pardeep Nijhawan reported holding 1,354,974 shares of Edesa Biotech (EDSA), worth about $2.56M at the last close of $2 (Nov 16, 2026): 952,272 held directly and 402,702 through a pardeep nijhawan medicine professional corporation. In the last 12 months, Pardeep Nijhawan bought $230K in 8 open-market purchases.
Edesa Biotech's proxy statement reports total compensation of $1.01M for Pardeep Nijhawan for fiscal year 2025, after $465K for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 3, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Edesa Biotech EDSA | 1,354,974 | 952K direct · 403K pardeep nijhawan medicine professional corporation | $2 | $2.56M | Nov 4, 2026 |
Is this Pardeep Nijhawan’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Pardeep Nijhawan reported 22 open-market purchases and 0 sales here, 2021 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Nov 4, 2026, Pardeep Nijhawan reported holding 1,354,974 shares of Edesa Biotech (EDSA), of which 402,702 are held indirectly. At the last close of $2 on Nov 16, 2026, that is about $2.56M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Pardeep Nijhawan reported 8 open-market purchases worth $230K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Edesa Biotech's proxy statement reports total compensation of $1.01M for Pardeep Nijhawan for fiscal year 2025, after $465K for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Pardeep Nijhawan bought shares on the open market in 2021, 2022, 2024 and 2026.
In SEC filings since 2021: the latest open-market purchase is from 2026; no open-market sale is on record.
Edesa Biotech (EDSA), from 2021 to 2026: 22 purchases and 0 sales.
Pardeep Nijhawan bought shares on the open market in 2021, 2022, 2024 and 2026.
Pardeep Nijhawan reported 22 open-market purchases and 0 sales since 2021; purchases in 4 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $230K8×8 trades | — |
| 2024 | $20K1×1 trade | — |
| 2022 | $71K11×11 trades | — |
| 2021 | $42K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.